Standard and innovative options in the treatment of insulin resistance
Keywordsinsulin resistance, treatment, FGF-21, metformin, SGLT-2 inhibitors
Introduction and purpose
Insulin resistance is a state of decreased tissue sensitivity to insulin, despite normal or elevated levels of this hormone in the blood serum. People with insulin resistance for a long time do not show symptoms, which makes it particularly difficult to detect and treat in early stages. It mainly leads to impaired glucose homeostasis and the development of type 2 diabetes, which contributes to the exacerbation of the global problem that diabetes has become. This results in the search for innovative therapies that will help combat insulin resistance better and better. The purpose of this study is to highlight the complexity of the IR and review the current literature for non-pharmacological and pharmacological possibilities of treatment for insulin resistance.
Description of the state of knowledge
Due to the increase in obesity and the metabolic syndrome, the number of people suffering from insulin resistance is constantly increasing. In modern times, there are various diagnostic and therapeutic methods that affect the course of insulin resistance. Early detection and introduction of appropriate therapy become the main goal in preventing complications that may occur in the course of this disease.
Treatment methods for insulin resistance can be divided into two groups - non-pharmacological and pharmacological. Both of them are often used together in the form of combination therapy aimed at obtaining the best results in the treatment of insulin resistance. For people for whom known therapies do not work, researches for new treatments is becoming a hope.
Freeman AM, Pennings N (2021). Insulin Resistance - StatPearls - NCBI Bookshelf. StatPearls Publishing, Treasure Island (FL). https://www.ncbi.nlm.nih.gov/books/NBK507839/
Sampath Kumar A, Maiya AG, Shastry BA, Vaishali K, Ravishankar N, Hazari A, Gundmi S, Jadhav R (2019). Exercise and insulin resistance in type 2 diabetes mellitus: A systematic review and meta-analysis. Annals of Physical and Rehabilitation Medicine, 62(2), 98–103. https://doi.org/10.1016/j.rehab.2018.11.001
Fahed M, Abou Jaoudeh MG, Merhi S, Mosleh JMB, Ghadieh R, Al Hayek, Al Hayek S, El Hayek Fares JE (2020). Evaluation of risk factors for insulin resistance: A cross sectional study among employees at a private university in Lebanon. BMC Endocrine Disorders, 20(1), 1–14. https://doi.org/10.1186/s12902-020-00558-9
Placzkowska S, Pawlik-Sobecka L, Kokot I, Piwowar A (2019). Indirect insulin resistance detection: Current clinical trends and laboratory limitations. Biomedical Papers, 163(3), 187–199. https://doi.org/10.5507/bp.2019.021
Soumya D, Srilatha B (2011). Late Stage Complications of Diabetes and Insulin Resistance. Journal of Diabetes & Metabolism, 02(09), 1–7. https://doi.org/10.4172/2155-6156.1000167
Suliburska J, Uśnierek J (2010). Czynniki żywieniowe i pozażywieniowe w rozwoju insulinooporności. Forum Zaburzeń Metabolicznych, 1(3), 177–183. Polish.
Pasek I, Wiska L, Kopytko P, Banach B (2021). Methods of treatment of obesity in patients with type 2 diabetes. Farmacja Polska, 77(7), 442–450. https://doi.org/10.32383/farmpol/142112 . Polish.
Strojek K, Wróbel M, Szymborska-Kajanek A, Rokicka D (2013). Metformina - Nowe wskazania refundacyjne. Diabetologia Kliniczna, 2(4), 120–124.
Saluja M, Pareek KK, Swami YK (2020). Study of Diversity of Metformin Related Gastrointestinal Side Effects. The Journal of the Association of Physicians of India, 68(8), 36–38. http://europepmc.org/abstract/MED/32738838
Flory J, Lipska K (2019). Metfonim in 2019. Jama, 321(19), 1926–1927. https://doi.org/10.1001/jama.2019.3805.Metformin
Knudsen LB, Lau J (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 10 (APR). https://doi.org/10.3389/fendo.2019.00155
Pegah A, Abbasi-Oshaghi E, Khodadadi I, Mirzaei F, Tayebinia H (2021). Probiotic and resveratrol normalize GLP-1 levels and oxidative stress in the intestine of diabetic rats. Metabolism Open, 10, 100093. https://doi.org/10.1016/j.metop.2021.100093
Wharton S, Davies M, Dicker D, Lingvay I, Mosenzon O, Rubino DM, Pedersen SD (2022). Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine, 134(1), 14–19. https://doi.org/10.1080/00325481.2021.2002616
Lebovitz HE (2019). Thiazolidinediones: the Forgotten Diabetes Medications. Current Diabetes Reports, 19(12), 1–13. https://doi.org/10.1007/s11892-019-1270-y
Karbowiak P, Rzeszotarski J, Walasek L (2013). Inhibitory kotransportera glukozowo- doustnych leków przeciwcukrzycowych. 191–197.
Xu L, Ota T (2018). Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization. Adipocyte, 7(2), 121–128. https://doi.org/10.1080/21623945.2017.1413516
Verma S, McMurray JJV (2018). SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 61(10), 2108–2117. https://doi.org/10.1007/s00125-018-4670-7
Jasik M (2010). Inhibitory dipeptydylopeptydazy 4 ( DPP-4 ) ze szczególnym uwzględnieniem sitagliptyny. Wybrane Problemy Kliniczne, 1(4), 220–229
Ghorbani Y, Schwenger KJP, Allard JP (2021). Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes. European Journal of Nutrition, 60(5), 2361–2379. https://doi.org/10.1007/s00394-021-02520-4
Soleimani A, Zarrati Mojarrad M, Bahmani F, Taghizadeh M, Ramezani M, Tajabadi-Ebrahimi M, Jafari P, Esmaillzadeh A, Asemi Z (2017). Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects. Kidney International, 91(2), 435–442. https://doi.org/10.1016/j.kint.2016.09.040
Doron S, Snydman DR (2015). Risk and safety of probiotics. Clinical Infectious Diseases, 60(Suppl 2), S129–S134. https://doi.org/10.1093/cid/civ085
Wang W, Zhang J, Wang H, Wang X, Liu S (2019). Vitamin D deficiency enhances insulin resistance by promoting inflammation in type 2 diabetes. International Journal of Clinical and Experimental Pathology, 12(5), 1859–1867. http://www.ncbi.nlm.nih.gov/pubmed/31934009%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6947100
Abbasi Oshaghi E, Goodarzi MT, Higgins V, Adeli K (2017). Role of resveratrol in the management of insulin resistance and related conditions: Mechanism of action. Critical Reviews in Clinical Laboratory Sciences, 54(4), 267–293. https://doi.org/10.1080/10408363.2017.1343274
Jimenez V, Jambrina C, Casana E, Sacristan V, Muñoz S, Darriba S, Rodó J, Mallol C, Garcia M, León X, Marcó S, Ribera A, Elias I, Casellas A, Grass I, Elias G, Ferré T, Motas S, Franckhauser S, Mulero F, Navarro M, Haurigot V, Ruberte J, Bosch F (2018). FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Molecular Medicine, 10(8), 1–24. https://doi.org/10.15252/emmm.201708791
How to Cite
Copyright (c) 2022 Jakub Metelski, Katarzyna Krauze-Kuc, Aleksandra Metelska, Dominika Sereda, Hubert Nieścior
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 128
Number of citations: 0